167 related articles for article (PubMed ID: 37323223)
1. Clinical utility of urinary mulberry bodies/cells testing in the diagnosis of Fabry disease.
Nakamura K; Mukai S; Takezawa Y; Natori Y; Miyazaki A; Ide Y; Takebuchi M; Nanato K; Katoh M; Suzuki H; Sakyu A; Kojima T; Kise E; Hanafusa H; Kosho T; Kuwahara K; Sekijima Y
Mol Genet Metab Rep; 2023 Sep; 36():100983. PubMed ID: 37323223
[TBL] [Abstract][Full Text] [Related]
2. The prevalence of Fabry disease among 1009 unrelated patients with hypertrophic cardiomyopathy: a Russian nationwide screening program using NGS technology.
Savostyanov K; Pushkov A; Zhanin I; Mazanova N; Trufanov S; Pakhomov A; Alexeeva A; Sladkov D; Asanov A; Fisenko A
Orphanet J Rare Dis; 2022 May; 17(1):199. PubMed ID: 35578305
[TBL] [Abstract][Full Text] [Related]
3. The Ckd. Qld fabRy Epidemiology (aCQuiRE) study protocol: identifying the prevalence of Fabry disease amongst patients with kidney disease in Queensland, Australia.
Mallett A; Kearey P; Cameron A; Healy H; Denaro C; Thomas M; Lee VW; Stark S; Fuller M; Hoy WE
BMC Nephrol; 2020 Feb; 21(1):58. PubMed ID: 32087678
[TBL] [Abstract][Full Text] [Related]
4. Fabry disease screening in high-risk populations in Japan: a nationwide study.
Yoshida S; Kido J; Sawada T; Momosaki K; Sugawara K; Matsumoto S; Endo F; Nakamura K
Orphanet J Rare Dis; 2020 Aug; 15(1):220. PubMed ID: 32843101
[TBL] [Abstract][Full Text] [Related]
5. Higher rate of rheumatic manifestations and delay in diagnosis in Brazilian Fabry disease patients.
Rosa Neto NS; Bento JCB; Pereira RMR
Adv Rheumatol; 2020 Jan; 60(1):7. PubMed ID: 31907047
[TBL] [Abstract][Full Text] [Related]
6. Nationwide screening for Fabry disease in unselected stroke patients.
Tomek A; Petra R; Paulasová Schwabová J; Olšerová A; Škorňa M; Nevšímalová M; Šimůnek L; Herzig R; Fafejtová Š; Mikulenka P; Táboříková A; Neumann J; Brzezny R; Sobolová H; Bartoník J; Václavík D; Vachová M; Bechyně K; Havlíková H; Prax T; Šaňák D; Černíková I; Ondečková I; Procházka P; Rajner J; Škoda M; Novák J; Škoda O; Bar M; Mikulík R; Dostálová G; Linhart A;
PLoS One; 2021; 16(12):e0260601. PubMed ID: 34905550
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive testing algorithm for the diagnosis of Fabry disease in males and females.
Stiles AR; Zhang H; Dai J; McCaw P; Beasley J; Rehder C; Koeberl DD; McDonald M; Bali DS; Young SP
Mol Genet Metab; 2020 Jul; 130(3):209-214. PubMed ID: 32418857
[TBL] [Abstract][Full Text] [Related]
8. FDrisk: development of a validated risk assessment tool for Fabry disease utilizing electronic health record data.
Lobel CJ; Laney DA; Yang J; Jacob D; Rickheim A; Ogg CZ; Clynes D; Dronen J
J Rare Dis (Berlin); 2024; 3(1):2. PubMed ID: 38187171
[TBL] [Abstract][Full Text] [Related]
9. In Patients with an α-Galactosidase A Variant, Small Nerve Fibre Assessment Cannot Confirm a Diagnosis of Fabry Disease.
van der Tol L; Verhamme C; van Schaik IN; van der Kooi AJ; Hollak CE; Biegstraaten M
JIMD Rep; 2016; 28():95-103. PubMed ID: 26563328
[TBL] [Abstract][Full Text] [Related]
10. The clinical utility of total concentration of urinary globotriaosylsphingosine plus its analogues in the diagnosis of Fabry disease.
Alharbi FJ; Baig S; Rambhatla SB; Vijapurapu R; Auray-Blais C; Boutin M; Steeds R; Wheeldon N; Dawson C; Geberhiwot T
Clin Chim Acta; 2020 Jan; 500():120-127. PubMed ID: 31654629
[TBL] [Abstract][Full Text] [Related]
11. Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene.
Ferri L; Guido C; la Marca G; Malvagia S; Cavicchi C; Fiumara A; Barone R; Parini R; Antuzzi D; Feliciani C; Zampetti A; Manna R; Giglio S; Della Valle CM; Wu X; Valenzano KJ; Benjamin R; Donati MA; Guerrini R; Genuardi M; Morrone A
Clin Genet; 2012 Mar; 81(3):224-33. PubMed ID: 21517827
[TBL] [Abstract][Full Text] [Related]
12. High-Risk Screening for Fabry Disease: A Nationwide Study in Japan and Literature Review.
Sawada T; Kido J; Sugawara K; Nakamura K
Diagnostics (Basel); 2021 Sep; 11(10):. PubMed ID: 34679477
[TBL] [Abstract][Full Text] [Related]
13. Nationwide screening of Fabry disease in patients with hypertrophic cardiomyopathy in Czech Republic.
Zemánek D; Januška J; Honěk T; Čurila K; Kubánek M; Šindelářová Š; Zahálková L; Klofáč P; Laštůvková E; Lichnerová E; Aiglová R; Lhotský J; Vondrák J; Dostálová G; Táborský M; Kasper D; Linhart A
ESC Heart Fail; 2022 Dec; 9(6):4160-4166. PubMed ID: 36087038
[TBL] [Abstract][Full Text] [Related]
14. Identification and functional characterization of the first deep intronic GLA mutation (IVS4+1326C>T) causing renal variant of Fabry disease.
Dai X; Zong X; Pan X; Lu W; Jiang GR; Lin F
Orphanet J Rare Dis; 2022 Jun; 17(1):237. PubMed ID: 35725559
[TBL] [Abstract][Full Text] [Related]
15. Diagnosing lysosomal storage disorders: Fabry disease.
Bodamer OA; Johnson B; Dajnoki A
Curr Protoc Hum Genet; 2013; Chapter 17():Unit17.13. PubMed ID: 23595598
[TBL] [Abstract][Full Text] [Related]
16. Urinary Mulberry Cells as a Biomarker of the Efficacy of Enzyme Replacement Therapy for Fabry Disease.
Aoyama Y; Ushio Y; Yokoyama T; Taneda S; Makabe S; Nishida M; Manabe S; Sato M; Kataoka H; Tsuchiya K; Nitta K; Mochizuki T
Intern Med; 2020; 59(7):971-976. PubMed ID: 32238663
[TBL] [Abstract][Full Text] [Related]
17. Deficiency in the Screening Process of Fabry Disease: Analysis of Chronic Kidney Patients Not on Dialysis.
Battaglia Y; Fiorini F; Azzini C; Esposito P; De Vito A; Granata A; Storari A; Mignani R
Front Med (Lausanne); 2021; 8():640876. PubMed ID: 33634157
[TBL] [Abstract][Full Text] [Related]
18. Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?
Duro G; Zizzo C; Cammarata G; Burlina A; Burlina A; Polo G; Scalia S; Oliveri R; Sciarrino S; Francofonte D; Alessandro R; Pisani A; Palladino G; Napoletano R; Tenuta M; Masarone D; Limongelli G; Riccio E; Frustaci A; Chimenti C; Ferri C; Pieruzzi F; Pieroni M; Spada M; Castana C; Caserta M; Monte I; Rodolico MS; Feriozzi S; Battaglia Y; Amico L; Losi MA; Autore C; Lombardi M; Zoccali C; Testa A; Postorino M; Mignani R; Zachara E; Giordano A; Colomba P
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30477121
[TBL] [Abstract][Full Text] [Related]
19. Cost Efficacy of α-Galactosidase A Enzyme Screening for Fabry Disease.
Newman DB; Miranda WR; Matern D; Peck DS; Geske JB; Maleszewski JJ; Ommen SR; Ackerman MJ
Mayo Clin Proc; 2019 Jan; 94(1):84-88. PubMed ID: 30611458
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of Fabry disease in dialysis patients: Western Australia Fabry disease screening study - the FoRWARD study.
Jahan S; Sarathchandran S; Akhter S; Goldblatt J; Stark S; Crawford D; Mallett A; Thomas M
Orphanet J Rare Dis; 2020 Jan; 15(1):10. PubMed ID: 31931840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
